Acelyrin, Inc. (NASDAQ:SLRN) CEO Sells $49,281.64 in Stock

Acelyrin, Inc. (NASDAQ:SLRN) CEO Mina Kim sold 17,986 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the sale, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at $1,840,603.22. The trade was a 2.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Acelyrin Price Performance

Shares of NASDAQ:SLRN traded down $0.03 during midday trading on Wednesday, reaching $2.79. The company had a trading volume of 850,761 shares, compared to its average volume of 1,234,757. The stock has a market capitalization of $279.91 million, a P/E ratio of -1.13 and a beta of 1.25. The stock’s fifty day moving average price is $2.25 and its 200-day moving average price is $3.85. Acelyrin, Inc. has a one year low of $1.85 and a one year high of $8.59.

Acelyrin (NASDAQ:SLRN) last released its earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.07. As a group, sell-side analysts forecast that Acelyrin, Inc. will post -2.53 earnings per share for the current year.

Institutional Trading of Acelyrin

Several institutional investors and hedge funds have recently bought and sold shares of SLRN. ProShare Advisors LLC grew its position in shares of Acelyrin by 28.5% in the 4th quarter. ProShare Advisors LLC now owns 25,307 shares of the company’s stock worth $79,000 after acquiring an additional 5,617 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Acelyrin by 21.9% during the fourth quarter. Wells Fargo & Company MN now owns 52,014 shares of the company’s stock worth $163,000 after purchasing an additional 9,332 shares during the last quarter. Virtu Financial LLC acquired a new position in Acelyrin in the third quarter worth $50,000. HighTower Advisors LLC bought a new stake in Acelyrin during the third quarter valued at $50,000. Finally, XTX Topco Ltd acquired a new stake in shares of Acelyrin during the fourth quarter worth $33,000. Institutional investors and hedge funds own 87.31% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. HC Wainwright decreased their price target on Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Wells Fargo & Company lowered their price target on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Finally, Citigroup cut their price objective on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Acelyrin has an average rating of “Hold” and an average target price of $9.60.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.